The FDA has granted RMAT designation to detalimogene voraplasmid for the treatment of high-risk, BCG-unresponsive, NMIBC with CIS.

Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the ...